Microneedles as transdermal drug delivery system for enhancing skin disease treatment.
10.1016/j.apsb.2024.08.013
- Author:
Chaoxiong WU
1
;
Qingyu YU
1
;
Chenlu HUANG
1
;
Fangzhou LI
1
;
Linhua ZHANG
1
;
Dunwan ZHU
1
Author Information
1. State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China.
- Publication Type:Review
- Keywords:
Aesthetic skin issues;
Atopic dermatitis;
Diabetic wound;
Infected wound;
Microneedles;
Psoriasis;
Skin diseases;
Superficial tumor
- From:
Acta Pharmaceutica Sinica B
2024;14(12):5161-5180
- CountryChina
- Language:English
-
Abstract:
Microneedles (MNs) serve as a revolutionary paradigm in transdermal drug delivery, heralding a viable resolution to the formidable barriers presented by the cutaneous interface. This review examines MNs as an advanced approach to enhancing dermatological pathology management. It explores the complex dermis structure and highlights the limitations of traditional transdermal methods, emphasizing MNs' advantage in bypassing the stratum corneum to deliver drugs directly to the subdermal matrix. The discourse outlines the diverse typologies of MNs, including solid, coated, hollow, hydrogel, and dissolvable versions. Each type is characterized by its unique applications and benefits. The treatise details the deployment of MNs in the alleviation of cutaneous cancers, the administration of inflammatory dermatoses such as psoriasis and atopic dermatitis, and their utility in wound management. Additionally, the paper contemplates the prospects of MNs within the realm of aesthetic dermatology and the burgeoning market traction of cosmetic MN formulations. The review summarizes the scientific and commercial challenges to the clinical adoption of MN therapeutics, including dosage calibration, pharmacodynamics, biocompatibility, patient compliance, sterilization, mass production, and regulatory oversight. It emphasizes the need for ongoing research, innovation, and regulatory harmonization to overcome these obstacles and fully realize MNs' potential in treating skin diseases and improving patient welfare.
